Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of the art analytical comparability: a review.

Developments in biologicals·2005
Same author

An overview of scientific and regulatory issues for the immunogenicity of biological products.

Developments in biologicals·2003
Same author

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

Current pharmaceutical biotechnology·2002
Same author

Challenges with current technology for the detection, measurement and characterization of antibodies against biological therapeutics.

Developments in biologicals·2002
Same author

Progress in the use of biological assays during the development of biotechnology products.

Pharmaceutical research·2001
Same author

The World Health Organization International Collaborative Study for islet cell antibodies.

Diabetologia·2000

Related Experiment Video

Updated: Jul 20, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Setting specifications for potency assays--basic principles.

A R Mire-Sluis1

  • 1CancerVax Corporation, Carlsbad, CA 92008, USA. tms@cancervax.com

Developments in Biologicals
|June 25, 2002
PubMed
Summary

Thorough characterization and biological assays are crucial for consistent biological therapeutic production. Robust bioassays are essential for setting accurate potency specifications, ensuring product safety and efficacy.

Area of Science:

  • Biopharmaceutical Development
  • Analytical Chemistry
  • Pharmacology

Background:

  • Successful biological therapeutic development requires comprehensive physicochemical and biological characterization.
  • Batch-to-batch consistency is maintained through rigorous control and specification setting.
  • Biological activity assessment via functional assays is critical, with exceptions for binding proteins correlated to activity.

Purpose of the Study:

  • To emphasize the necessity of well-validated bioassays for potency specification.
  • To highlight the importance of minimizing variability in biological assays.
  • To guide the derivation of potency specifications based on assay validation and product characteristics.

Main Methods:

  • Designing and executing biological assays to minimize variability.

More Related Videos

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Jul 20, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

  • Establishing statistically valid measures for reproducibility of potency estimates.
  • Correlating binding assays with biological activity where applicable.

    • Main Results:

    • Biological assays are inherently prone to variability, necessitating careful design.
    • Validated bioassays are a prerequisite for setting meaningful potency specifications.
    • Potency specifications must incorporate variability measures and reflect product attributes.

    Conclusions:

    • Rigorous bioassay validation is fundamental for reliable potency assessment in biotherapeutics.
    • Potency specifications should encompass both the estimated potency and its associated variability.
    • Specification limits must consider product consistency, nature, toxicity, and intended use for safe and effective therapeutics.